A tax that doubles the import cost of a patented drug is now live for every pharmaceutical company that did not secure tariff relief. As of September 29, 2026, the Section 232 tariff on patented medicines and their active ingredients expanded to companies not listed in Annex III, completing the rollout that began for the largest manufacturers on July 31, 2026. The headline rate: 100%.
The split in who pays and who does not is worth understanding precisely, because it reshapes the risk calculus across the entire sector.
How the Exemptions Were Structured
Companies that have both a Commerce-approved onshoring plan and a most-favored-nation (MFN) pharmaceutical pricing agreement with the Department of Health and Human Services can receive a zero tariff rate through January 20, 2029. Annex III lists 17 large manufacturers, including Amgen, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, and Pfizer, whose tariff treatment became effective on July 31, 2026.
Pfizer has publicly said it committed an additional $70 billion to U.S. research, development, and capital projects as part of its agreement with the U.S. government.
Companies with only a Commerce-approved onshoring plan face a 20% rate, which rises to 100% on April 2, 2030. Everyone else pays the full 100% rate once the September 29, 2026 effective date applies.
Where the Cost Actually Lands
Companies that made MFN agreements are not on the hook for payment until early 2029, under those agreements. That exempts many of the biggest U.S. drugmakers, while leaving smaller biotech firms to face the levies. STAT News reported Thursday that many of those smaller firms say they are being left in the dark on how to obtain exemptions.
The financial math is unforgiving for clinical-stage companies. Many public biotech and life sciences companies are small-cap and run with limited cash runway. A 100% duty on imported active pharmaceutical ingredients does not hit revenue; it hits the bank account directly, in the form of higher manufacturing costs on every batch produced overseas.
The largest drugmakers have largely avoided this cost. The 17 large companies named in Annex III are the first group subject to the program, and MFN-linked relief can exempt qualifying companies from the tariff until January 20, 2029. Small and mid-size developers are the companies most exposed today.
Industry watchers note the tariffs are intended to pressure firms into more MFN drug pricing deals, but could just as easily convince some companies to sell out to big pharma or scale back operations. For a pre-revenue biotech burning $30 million a quarter, a forced sale at a distressed valuation is not a strategic outcome. It is a wipeout.
The Portfolio Argument for Large Pharma
This divergence between who pays and who does not is not a temporary imbalance waiting to be corrected. The MFN zero rate runs to January 20, 2029, and the names best positioned to qualify for it are the same names with the balance sheets, domestic manufacturing capacity, and regulatory relationships to sustain it. Pfizer, Merck, Lilly, Bristol Myers Squibb, and Amgen all enter this period with their investment pledges already announced.
For investors, the tariff structure effectively prices in a quality premium for large pharma over speculative biotech names. Because a smaller company cannot fund American plants, scale becomes the qualifying condition for the discount, and the pipeline that speculative biotech is built on would absorb that bill years from now.
The ETF picture tells part of the story. The iShares Biotechnology ETF, weighted by market value, leans toward larger companies. The equal-weighted SPDR S&P Biotech ETF holds many clinical-stage companies whose exposure to this tariff can be more acute, and whose fundraising environment just became more difficult, as every small-cap peer now carries a new operational cost that investors must price.
The Wealth-Building Takeaway
Policy risk in biotech has always been part of the investment calculus. What changed on September 29, 2026 is that the risk is no longer symmetric across the sector. Companies that qualify for MFN-linked relief can reach a zero tariff rate until January 20, 2029. Smaller biotechs without that leverage face either a 100% duty on imported drug ingredients, a costly restructuring toward domestic manufacturing, or acquisition pressure from the very large-cap names that now hold a structural cost advantage.
Owning quality in this environment is not merely a conservative preference. It is a direct response to a policy that rewards scale and punishes the companies least able to absorb a new tax on their core inputs.
